Member Exclusive NEWS ROUND-UP

Cell therapy weekly: StemGenex receives warning letter from FDA over unapproved cell therapy and facility with “significant violations”

This week in cell therapy: HemaCare supplies starting materials for three FDA approved cell therapies and Mesoblast defends stem cell-based therapy for heart failure.

Go to the profile of RegMedNet
Nov 15, 2018
0
0

Please sign in or register for FREE

No comments yet.